BioCentury | Feb 8, 2020
Product Development

Coronavirus biology: where products in clinical testing intervene

The 13 therapies in clinical trials to treat coronavirus map to at least half a dozen mechanisms, intervening at three different steps in the viral cycle or manipulating different aspects of the host immune response....
BC Week In Review | Dec 1, 2017
Company News

SciClone completes going private deal

A consortium of investors led by GL Capital and including Bank of China, CDH, Ascendent Capital Partners and Boying completed its acquisition of SciClone Pharmaceuticals Inc. for $11.18 per share in cash. The deal valued...
BC Week In Review | Jun 9, 2017
Company News

SciClone going private in $605M deal

SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) said it will be acquired by an investor syndicate led by GL Capital Management for $11.18 per share in cash, or about $605 million. Other investors include Bank of China Group...
BC Extra | Jun 8, 2017
Company News

SciClone going private in $605M deal

SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) said it will be acquired by an investor syndicate led by GL Capital Management for $11.18 per share in cash, or about $605 million. Other investors include Bank of China Group...
BC Innovations | Apr 13, 2017
Targets & Mechanisms

Cool and also collected

A Nature Medicine study published this week shows the immune-modulating peptide thymosin α1 provides unexpected improvements in the dysfunctional ion channel that causes cystic fibrosis, and could lead to a single agent therapy to compete...
BC Innovations | Apr 11, 2017
Distillery Therapeutics

Pulmonary; infectious disease

INDICATION: Cystic fibrosis (CF); fungal infection Patient sample and mouse studies suggest the PTMA -derived peptide thymosin α1 could help treat CF and CF-related pulmonary fungal infections. In primary bronchial epithelial cells from five CF...
BC Week In Review | Nov 18, 2016
Company News

SciClone deal

SciClone received an unsolicited bid from a consortium led by ABM Management Ltd. and GL Capital Management GP Ltd. to acquire all outstanding shares not already owned for $11.18 per share in cash. The price...
BC Week In Review | Oct 3, 2016
Clinical News

Thymalfasin: Phase III started

SciClone began a double-blind, placebo-controlled, Chinese Phase III trial to evaluate 1.6 mg subcutaneous Zadaxin twice daily for 7 days in 1,104 patients. SciClone’s Zadaxin is approved in >30 countries for HBV and HCV infection...
BC Week In Review | Feb 15, 2016
Company News

SciClone infectious news

SciClone agreed to pay $12.8 million to settle an SEC investigation into whether historical sales and marketing in SciClone’s China operations violated the Foreign Corrupt Practices Act. The company “neither admits nor denies it engaged...
BC Extra | Nov 11, 2015
Financial News

SciClone climbs on earnings

SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) jumped $1.67 (21%) to $9.66 on Tuesday after reporting earnings postmarket Monday and raising its FY15 EPS guidance. The company reported non-GAAP diluted EPS of $0.26 in 3Q15, up from $0.17...
Items per page:
1 - 10 of 202